Oscare Medical exhibits OsCare Sono® in the World Congress on Osteoporosis in Málaga

Oscare Medical will exhibit its unique low frequency ultrasound device for osteoporosis assessment, OsCare Sono®, at this year’s World Congress on Osteoporosis, Osteoarthritis and Musculosceletal Diseases. The WCO-IOF-ESCEO congress will take place in Málaga, Spain, from April 14th to 17th. With over 3,200 participants, it is the largest educational event and most vibrant clinical research forum for osteoporosis, osteoarthritis and musculoskeletal diseases in Europe.

Osteoporosis is estimated to affect 22 million women and 5.5 million men in Europe, with most of them unaware that they suffer from this silent disease until they suffer one or even several low energy fractures. The OsCare Sono® offers a convenient way to assess bone health and to identify individuals at risk for osteoporosis. The measurement is based on measuring the speed of low frequency ultrasound in the forearm radial bone using a compact, hand held device. The result correlates with bone cortical thickness, bone elasticity and bone mineral density (BMD), all important determinants of bone strength. You are warmly welcome to see the product and have your bone strength assessed at Oscare Medical’s booth, located at the Exhibition Area, Level 0, Booth 7.

Oscare Medical showcases its unique osteoporosis screening device in Arab Health 2016 together with distributor Z1 International

VANTAA, Finland — Oscare Medical announces that it will exhibit its unique low frequency ultrasound device, the OsCare Sono®, for osteoporosis assessment at this year’s Arab Health, together with its distributor in Middle East, Z1 International. Arab Health is Middle East’s largest medical exhibition and will be held on 25th – 28th January in Dubai, UAE.

The OsCare Sono® is a compact, hand-held device, offering a convenient way to assess bone health and to identify the individuals at risk for osteoporosis. The measurement is based on measuring the speed of low frequency ultrasound in the forearm radial bone. The results correlate with bone cortical thickness, bone elasticity and bone mineral density (BMD), all important determinants of bone strength.

The International Osteoporosis Foundation (IOF) considers osteoporosis a “neglected” disease in the Middle East. In an IOF audit from 2011, it was found out that education and lifestyle prevention programmes for the public are generally lacking. Access to densitometry and care is limited in many countries, often only available in urban areas. Despite the sunshine, the prevalence of vitamin D deficiency has been estimated to range between 50-90 % in most countries and across age groups. As in Europe, the prevalence of osteoporotic fractures in the Middle East is expected to rise further in the future. In some countries, e.g. Lebanon, Jordan, and Syria, the number of hip fractures is projected to quadruple by 2050.

The OsCare Sono® can help raise awareness on bone health and help individuals at high risk for osteoporosis receive attention and care.

Meditek appointed Oscare Medical’s distributor in Norway and Sweden

VANTAA, Finland – Oscare Medical announces that Meditek has been appointed as its distributor for the OsCare Sono® device for osteoporosis risk assessment in Norway and Sweden.

Meditek, established in 1992, is a medical technology distributor focused on lung medicine on one hand and endoscopy and ultrasound on the other. The company has been a “Gazelle Company” for four years in a row; 2011, 2012, 2013 and 2014. A Gazelle Company is a company that over four years has been increasing its revenue annually by at least 20 % (i.e. doubling its revenue over four years). Oscare Medical is delighted to sign up such a dynamic and ambitious distributor for its OsCare Sono® osteoporosis screening device.

In Norway about 300 000 people have osteoporosis, and 12 000 wrist and 9 000 hip fractures occur every year. Oslo women have the highest risk for hip fractures in the world. In Sweden 50 % of women and 25 % of men are evaluated to suffer an osteoporotic fracture during their lifetime. The OsCare Sono® will enable to identify patients at a high risk for osteoporosis so that they may be referred for further examinations. Cato Kolstad, CEO of Meditek, comments “The OsCare Sono® is a new innovative bone sonometer, which will make it possible for front line health services to identify patients with an increased risk of osteoporosis and direct them to appropriate further care, thus helping reduce the number of fractures and suffering. We are excited about taking the OsCare Sono® to the Norwegian and Swedish markets.”

For more information, please contact:
Meditek medisinsk utstyr AS
Rigedalen 15
4626 Kristiansand
Norway
T: +47 38 09 89 00
F: +47 38 04 60 00

Meditek medicinsk utrustning
Bultgatan 40B
442 40 Kungälv
Sweden
T: 010-2078330 / 0707-492100

http://www.meditek.no
E: meditek@meditek.no

Oscare Medical showcases novel ultrasound device for assessment of osteoporosis at Medica 2015

Promises to make screening for risk of osteoporosis simple, reliable and affordable

VANTAA, Finland – Oscare Medical Oy announces that it will be demonstrating its unique low frequency ultrasound device, the OsCare Sono® for osteoporosis assessment, at this year’s Medica in Hall 16, booth E57. Medica, the world’s largest medical exhibition, will be held on 16th – 19th November in Düsseldorf, Germany.

Osteoporosis, a bone condition that incurs an increasing risk of fracture, is a rapidly increasing problem for aging societies. The dual energy X-ray method (DXA) is the gold-standard for confirming a diagnosis of osteoporosis, but the expense, and limited availability, of DXA make it an impractical technique for screening people at an increased risk for osteoporosis. By assessing bone strength from the forearm radial bone using ultrasound, the OsCare Sono® allows for safe and inexpensive assessment of an individual’s risk for osteoporosis.

OsCare Sono® measurements have been shown to correlate with bone cortical thickness, bone elasticity and bone mineral density (BMD), including BMD of the deeper cortical layers – suggesting that the device uniquely offers enhanced sensitivity to early osteoporotic changes. Research also indicates that the OsCare Sono® can help identify people at an increased risk for osteoporosis and therefore those individuals who may benefit from further diagnostics.

A large 250-patient study is underway to determine how well OsCare Sono® measurements correlate with microstructural bone parameters as defined by high-resolution peripheral quantitative computed tomography. The ability of the Oscare Sono® to discriminate between individuals according to their fracture history is also being assessed as part of this study, led by Professor Serge Ferrari, Head of Department, Service of Bone Diseases at Geneva University Hospital, Switzerland.

About OsCare Sono®

The OsCare Sono® is a compact, hand-held device designed for osteoporosis risk assessment in clinics and low-threshold locations, such as high street pharmacies. The device attaches via a USB connector to a standard PC. A measurement is taken from the forearm over a few minutes using harmless ultrasound. An individual’s measurement is compared to the normal value observed in healthy young women, and the final OsCare Sono® result is ready within seconds for counseling.

About Oscare Medical

Oscare Medical was founded in 2007 to commercialize the results of a decade of research into bone health at the University of Jyväskylä, Finland. Since 2013, Oscare Medical has been majority-owned by Nasdaq-OMX-listed Revenio Group Corp which also markets the hugely successful Icare® tonometer product family. The OsCare Sono® is CE-marked and is on sale in several European countries. Oscare Medical is now rapidly expanding its distribution partner network. See: www.oscaremedical.com.

Contact:

Mervi Turunen
Sales & Marketing Manager
T: +358 40 732 4904
E-mail: mervi.turunen@oscaremedical.fi

Visit us at Medica 2015

Oscare Medical will be presenting their unique solution for early osteoporosis assessment at Medica 2015 in Düsseldorf from Monday 16th to Thursday 19th of November. Welcome to visit us in hall 16 booth E57, to learn more about the easy and reliable bone strength measurement and to get an assessment of your own bone health.

Oscare Medical collaborates in Clinical Study with Geneva University Hospital

Oscare Medical has signed a Clinical Study Agreement with Geneva University Hospital (HUG) on the study titled “Low-frequency axial ultrasound velocity in elderly men and women from the Geneva Retirees Cohort: correlations with cortical thickness and porosity assessed by high-resolution peripheral quantitative computed tomography and associations with fracture history”. The research is conducted in the Service of Bone Diseases by Professor Serge Ferrari, with Dr. Emmanuel Biver and Dr. Jessica Pepe.

The study will be the first one to look at the correlation of axial low-frequency ultrasound velocity (VLF) measured with OsCare Sono™ from the distal radius with bone parameters defined by high-resolution peripheral quantitative computed tomography (HR-pQCT). HR-pQCT provides information on cortical and trabecular microstructure down to 80 µm resolution. Earlier studies have already shown a good correlation between VLF measured by OsCare Sono™ and cortical thickness as well as bone density assessed with peripheral quantitative computed tomography (pQCT). The present study will also look at the capacity of VLF to discriminate subjects according to fracture history.

Professor Ferrari has published more than 200 articles and book chapters on bone mass acquisition in childhood, osteoporosis and bone and mineral metabolism. He is past president of the Swiss Bone and Mineral Society and Vice-President of the Swiss Association against Osteoporosis, and vice chair of the Committee of Scientific Advisors of the International Osteoporosis Society. Dr. Biver’s research interests include the bone and muscular determinants of fragility fractures. In 2014 Dr. Biver won several research awards, including Amgen Swiss Bone and Mineral Society president award and the IOF Servier Young Investigator Research Grant. Dr. Pepe is a visiting research MD from Professor Minisola’s research group in the Sapienza University in Rome. Her research interests include osteoporosis and primary hyperparathyroidism.

Data collection for the study has begun in August 2015, and the study results will be published by June 2017.

New distributor for Oscare Medical in the United Kingdom

VANTAA, Finland – Oscare Medical Oy announces that Physiological Measurements Limited (PML) is now distributing OsCare Sono™ for osteoporosis risk assessment in the United Kingdom. PML is an award winning provider of diagnostic investigations in hospital and community settings, as well as a provider of high tech medical products. PML aims to provide patients with high quality investigations utilising the latest innovative technology.

Oscare Medical to exhibit OsCare Sono™ in the World Congress on Osteoporosis in Milan

Oscare Medical Oy will exhibit its novel, low frequency ultrasound-based device for assessing bone strength, OsCare Sono™, at this year’s World Congress on Osteoporosis, Osteoarthritis and Musculosceletal Diseases. The WCO-IOF-ESCEO congress will take place in Milan, Italy, from March 26th to 29th. With over 4,500 participants, this is the largest educational event and most vibrant clinical research forum for osteoporosis, osteoarthritis and musculoskeletal diseases in Europe.

The OsCare Sono™ is a compact, hand-held device, offering a convenient way to assess bone health and to identify the individuals at risk for osteoporosis. The assessment is based on measuring the speed of low frequency ultrasound in the forearm radial bone – as the low frequency ultrasound penetrates deep into the bone and travels throughout the cortical layer, it is able to provide a good correlation with cortical layer thickness, bone density and elasticity of the bone – all important determinants of bone strength. You are warmly welcome to see the product and have your bone strength assessed at Oscare Medical’s booth, located at MiCo North, Level +1, Booth 6.

Espansione to distribute OsCare Sono™ in Italy

VANTAA, Finland — Oscare Medical Oy announces that the Espansione Marketing SPA, part of the Bologna-based Espansione Group, is now distributing the OsCare Sono™ for osteoporosis assessment. Espansione is an established manufacturer and marketer of medical equipment with a special focus on the pharmacy market as a distribution channel in Italy. Life expectancy in Italy is one of the highest in the world and the high prevalence of osteoporosis leads to annual costs from major fracture sites being over one billion euro.

Ms. Morena Gomedi, International Operations Manager of Espansione Marketing commented, “Pharmacists can play a key role in osteoporosis screening and treatment, we are therefore pleased to be able to offer pharmacies in Italy the most cost-effective and easy-to-use osteoporosis device available.”

With over 18,000 pharmacies, Italy represents one of the largest national pharmacy markets in Europe. Espansione will be adding the OsCare Sono™ to the range of specialized products they promote to pharmacists, including the Icare range of tonometers.

For more information, please contact:
Espansione Marketing SPA
Blocco 27 – Via degli Orefici 152
Centergross 40050 Funo
BOLOGNA
Tel: (+39) 051 8901611
Fax: (+39) 051 863400

www.espansionegroup.it
E-mail: info@espansione.it

New distributor for Oscare Medical in Poland

VANTAA, Finland — Oscare Medical Oy announces that Forel Medical, a Warsaw-based distributor of advanced medical technologies is now distributing the OsCare Sono™ for osteoporosis assessment. Forel Medical will be adding the OsCare Sono™ to the range of products they are already promoting to customers in markets such as gynecology and private clinics. Wojciech Borkowski, General Manager of Forel Medical commented, “We are very pleased to add a truly novel ultrasound-based osteoporosis assessment device to our portfolio. There is increasing awareness of osteoporosis in Poland, and before the OsCare Sono™, there has not been a patient-friendly and cost-effective product available on the market for screening.”

For more information, please contact:
Forel Medical
ul. Szczera 13
02-482 Warszawa
T: +48 22 631 29 24
F: +48 22 631 27 02
www.forelmedical.pl
E: info@forelmedical.pl